MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:

• Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
• Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
• 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.

Archived webcasts will be available on MacroGenics' website.

ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following virtual conferences in February 2022.

• Guggenheim Healthcare Talks | 2022 Oncology Conference.  MacroGenics’ management will participate in a fireside chat on Thursday, February 10, 2022, at 9:00 am ET.  Management will also participate in one-on-one meetings.
• Citi’s 2022 Virtual Immuno-Oncology Summit.  MacroGenics’ management will participate in a fireside chat on Thursday, February 17, 2022, at 12:30 pm ET.
• 11^th Annual SVB Leerink Global Healthcare Conference.  MacroGenics’ management will participate in a fireside chat on Friday, February 18, 2022, at 10:40 am ET.  Management will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

FAQ

What conferences will MacroGenics participate in February 2022?

MacroGenics will participate in the Guggenheim Healthcare Talks on February 10, Citi’s Virtual Immuno-Oncology Summit on February 17, and the SVB Leerink Global Healthcare Conference on February 18.

What is the ticker symbol for MacroGenics?

The ticker symbol for MacroGenics is MGNX.

Where can I find the webcasts for MacroGenics' presentations?

Webcasts for MacroGenics' presentations can be accessed under the 'Events & Presentations' section on their Investor Relations website.

What type of therapies does MacroGenics develop?

MacroGenics develops innovative monoclonal antibody-based therapeutics primarily for the treatment of cancer.

What is the date of the Guggenheim Healthcare Talks conference?

The Guggenheim Healthcare Talks will take place on February 10, 2022.

When is the SVB Leerink Global Healthcare Conference?

The SVB Leerink Global Healthcare Conference will be held on February 18, 2022.